Is Sonidegib on the market?

Sonidegib is a Hedgehog signaling pathway inhibitor (through smooth antagonism), developed by Novartis as an anti-cancer agent. It was approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of locally advanced recurrent basal cell carcinoma (BCC) after surgery and radiation therapy. It is also approved for use in patients when surgery or radiation therapy is not appropriate.

The Hedgehog pathway is involved in many human cancers, and Solidagen effectively inhibits a regulatory factor called smoothened (Smo), preventing the function of the Hedgehog pathway. Therefore, tumors that rely on the hedgehog pathway cannot grow. The area under the curve (AUC) and maximum concentration (Cmax) of Solidagib were within the dose range of 100-400 mg, but at doses greater than 400 mg, the increase was less than dose proportional. Steadygeb reaches a steady state about 4 months after starting Solidagen, and the estimated accumulation at steady state is 19 times. After a once-daily 200 mg dose, the estimated mean steady-state Cmax was 1030 ng/mL, AUC0-24 hours was 22 mcg*hour/mL, and the lowest concentration was 890 ng/mL.

Solidagen is a new type of drug for treating diseases. Although the original drug Solidagen has been marketed in China, it has not yet entered the scope of medical insurance, and its price has not yet been determined. The Original drug Solidaget listed overseas, European version specificationsThe price per box of 200mg*30 tablets is around RMB 46,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. The ingredients of the two drugs are basically the same. There is currently no generic version of Solidaget produced and marketed. For specific prices and drug information, please consult Yaodei Medical Consultants.